EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico

María Elena Camacho Moll, Ana Maria Salinas Martínez, Minna Wu, Gloria Navarrete Floriano, Juan Carlos Romo Salazar, Jorge Eleazar Cruz Luna, Mario Bermúdez de León

Journal of Infection and Public Health · 2024

DOI: 10.1016/j.jiph.2024.05.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Infection and Public Health, 2024. Verfasst von María Elena Camacho Moll und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Northeast Biomedical Research Center, Mexican Institute of Social Security. Monterrey, Mexico; Health Sciences Divis…. Hauptthemen laut MEDLINE: Hospitalization, COVID-19, SARS-CoV-2. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Information on Paxlovid™ effectiveness must be monitored and updated in real world scenarios. Our research question was what is the effectiveness of Paxlovid™ in adult patients with COVID-19? Therefore, we investigated the effectiveness of Paxlovid™ on reducing the incidence of pneumonia, hospitalization, and mortality in a cohort of COVID-19 positive adult patients from northeast Mexico. METHODS: A retrospective cohort study of COVID-19 positive adult patients from Nuevo Leon, Mexico from December 2020 to May 2023 (after Omicron BA-5 circulation) was performed. Paxlovid™ use was authorized in September 2022. Therefore, we analyzed effectiveness in patients with confirmed diagnosis who met selection criteria between September 2022 and May 2023 (n = 20,799; 5,673 with and 15,126 without Paxlovid™). RESULTS: The pneumonia (0.1% vs. 0.4%, p < 0.0001), hospitalization (0.1% vs. 1.2%, p < 0.0001), and death rates (0.04% vs. 0.2%, p < 0.0001) were lower in patients with Paxlovid™ treatment independently of age, sex, comorbidity, and COVID-19 and pneumococcal vaccination history. Effectiveness was 88.2%, 95.9% y 91.9% for pneumonia, hospitalization, and death, respectively. CONCLUSIONS: Paxlovid™ reduces the presentation of pneumonia, hospitalization, and death secondary to COVID-19. It is recommended to continue monitoring Paxlovid™ effectiveness, as other SARS-CoV-2 variants continue to emerge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationCOVID-19SARS-CoV-2HumansMaleMexicoFemaleRetrospective StudiesMiddle AgedIncidenceAdultAgedCOVID-19 Drug TreatmentPneumoniaAged, 80 and over

Stichwörter der Autor:innen

COVID-19DeathDrug combinationHospitalizationNirmatrelvir and ritonavir

Autor:innen und Institutionen

  • Department of Molecular Biology, Northeast Biomedical Research Center, Mexican Institute of Social Security. Monterrey, Mexico; Health Sciences Division, Center for Molecular Diagnosis and Personalized Medicine, Univers…
  • School of Public Health and Nutrition, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico. Electronic address: amsalinasmartinez@gmail.com.
  • Family Medicine Unit No. 64, Mexican Institute of Social Security. Santa Catarina, Nuevo Leon, Mexico; Faculty of Medicine, Universidad de Monterrey, San Pedro Garza García, Mexico.
  • Medical Epidemiological Assistance Coordination of the State of Nuevo León, Mexican Social Security Institute, Monterrey, Nuevo León, Mexico.
  • Department of Molecular Biology, Northeast Biomedical Research Center, Mexican Institute of Social Security. Monterrey, Mexico.

Zitieren

APA

Camacho Moll, M. E., Martínez, A. M. S., Wu, M., Floriano, G. N., Salazar, J. C. R., Luna, J. E. C., & de León, M. B. (2024). Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico. Journal of Infection and Public Health. https://doi.org/10.1016/j.jiph.2024.05.001

Vancouver

Camacho Moll ME, Martínez AMS, Wu M, Floriano GN, Salazar JCR, Luna JEC, et al. Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico. Journal of Infection and Public Health. 2024. doi:10.1016/j.jiph.2024.05.001

BibTeX
@article{CamachoMoll2024,
  author = {Camacho Moll, María Elena and Martínez, Ana Maria Salinas and Wu, Minna and Floriano, Gloria Navarrete and Salazar, Juan Carlos Romo and Luna, Jorge Eleazar Cruz and de León, Mario Bermúdez},
  title = {Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico},
  journal = {Journal of Infection and Public Health},
  year = {2024},
  doi = {10.1016/j.jiph.2024.05.001}
}
Kostenlos starten →